Nano-X Imaging Ltd. — Form 6-K Summary
Business Context and Reporting Period
Nano-X Imaging Ltd. filed this Form 6-K for November 2021, dated November 8, 2021. The filing reports three acquisitions completed in early November 2021 to expand the Company’s medical-imaging, artificial-intelligence, radiology-services, and healthcare-technology capabilities.
Key Financial and Transaction Metrics
- Zebra Medical Vision Ltd.: Merger completed November 4, 2021. Nano-X issued 3,249,142 ordinary shares and committed to issue 133,207 employee options and restricted stock units. The basic purchase price was $100.0 million, subject to transaction costs and specified adjustments.
- The Zebra consideration included $3.3 million for a designated commercial agreement and $6.3 million for achievement of a specified FDA clearance milestone. Two additional commercial agreements could trigger $3.3 million of additional share consideration per agreement.
- Additional Zebra milestone consideration of up to $77.7 million may be payable in shares over the next three years, subject to FDA clearances, security certifications, technology integration, revenue, and employee-retention targets.
- USARAD Holdings, Inc.: Acquisition completed November 2, 2021. Nano-X paid $7.3 million in cash and issued 496,545 ordinary shares valued at $23.16 per share. Additional consideration may include up to $2.0 million in cash and $6.5 million in shares, contingent on profitability, EBITDA, and other operating milestones.
- MDWEB, LLC: Acquisition of the platform and other assets completed November 3, 2021. Nano-X issued 61,487 ordinary shares valued at $23.18 per share. Up to $1.5 million of additional share consideration may be payable based on technical integration and other operating milestones.
The filing does not provide revenue, net income, cash-flow, margin, debt, liquidity, or pro forma financial results for the reporting period.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative financial statements or operating results. The material changes disclosed are the completion of the Zebra, USARAD, and MDWEB acquisitions, together with related share issuance, cash payments, and contingent consideration obligations.
Guidance, Outlook, Risks, and Unusual Items
- Zebra was renamed Nanox AI Ltd. and will operate under that name.
- Contingent consideration could result in substantial future share dilution and, for USARAD, additional cash payments.
- Future payments depend on commercial agreements, regulatory clearances, security certifications, technology integration, profitability, EBITDA, revenue, employee retention, and other operating milestones; achievement is not assured.
- The filing provides no formal revenue or earnings guidance and no broader management outlook.
Important Facts for Investors to Verify
- The final accounting treatment, purchase-price allocation, goodwill, and acquired intangible assets for each transaction.
- The number of ordinary shares outstanding after the acquisitions and the potential dilution from committed and contingent equity consideration.
- Whether the specified commercial, regulatory, integration, profitability, EBITDA, revenue, and retention milestones are achieved.
- The cash funding sources and liquidity impact of the $7.3 million USARAD payment and any future cash obligations.
- Post-acquisition revenue, expenses, cash flow, and operating performance, which are not provided in this filing.